title: [Effects of entecavir and Shenxian Yiganling combination therapy on patients with HBeAg-positive chronic hepatitis B for 48 weeks].
abstract: OBJECTIVE
  To evaluate of the efficacy and safety of entecavir (ETV) combined with Shenxian Yiganling (SY) versus ETV therapy on patients with HBeAg-positive chronic hepatitis B (CHB) for 48 weeks.
  
  
  METHODS
  One hundred and sixty-four CHB patients were assigned to two groups with the cohort study: the ETV combined with SY treatment group and the ETV control group. The alanine aminotransferase (ALT), the undetectable HBV DNA level, and HBeAg negative conversion rate, and HBeAg serological negative conversion rate were observed before and after treatment.
  
  
  RESULTS
  At week 48, there was no significant difference in the normalization of ALT levels (70.00% vs 67.61%, P > 0.05) and undetectable HBV DNA levels (72.50% vs 73.24%, P > 0.05) between the two groups. There was significant difference in the HBeAg negative conversion rate (39.44% vs 23.75%) and HBeAg serological negative conversion rate (32.39% vs 15.00%) (both P < 0.05).
  
  
  CONCLUSIONS
  ETV combined with SY promoted the HBeAg serological negative conversion rate possibly through the recovery of the immune functions.
authors.affiliation: Department of Infectious Diseases, First Affiliated Hospital, Hunan University of Traditional Chinese Medicine, Changsha (410007).
authors.forename: Tao
authors.initials: T
authors.lastname: Zhang
authors.forename: Ya
authors.initials: Y
authors.lastname: Wang
authors.forename: Ke-Wei
authors.initials: KW
authors.lastname: Sun
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006513:Hepatitis B e Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D011446:Prospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D004365:Drugs, Chinese Herbal; D006513:Hepatitis B e Antigens; C413685:entecavir; D006147:Guanine